Linklaters has named longtime New York partner Tom McGrath as its new US global practice head, replacing Tom Shropshire, who is leaving the firm to take up the position of general counsel at alcoholic beverages giant Diageo.
McGrath, who has led Linklaters’ US antitrust and foreign investment group since joining the firm in 2005, will begin his four-year term immediately. In his new role, he will be responsible for driving growth in the US, and he will also sit on the firm’s executive committee.
Tom joined Linklaters in 2005 as a partner in New York. Since that time, he has served as head of Linklaters’ US Antitrust & Foreign Investment Group. He has been a member of the Firm’s Partnership Board, and is co-head of the firm’s Global Healthcare Group. Tom advises US and international clients on the antitrust aspects of multinational merger clearances and defends clients in criminal price-fixing investigations and private antitrust litigation.
He has acted for clients on some of the world’s most complex and high-profile transactions which include advising Linde AG on its US$90 billion global merger of equals with Praxair creating the world’s largest industrial gas supplier; Novartis on its transformational transactions with GlaxoSmithKline; and Takeda in relation to its US$62 billion offer for Shire, which was the largest ever outbound M&A deal by a Japanese company. Tom will continue to advise clients and retain his current client work in addition to his new leadership role.
Commenting on Tom’s appointment, Linklaters’ Firmwide Managing Partner Gideon Moore, said, “I am delighted to have Tom step into this role. I know he will do a great job ensuring we continue to build and retain a best-in-class Global US Practice.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
